Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 9
Treatment-assignment count: 0
Stratification count: 2
Manual Review Required
PD-L1 expression
NSCLC · Monoclonal Antibody
PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 26 contexts. FDA CDx context exists. Threshold text varies across public records.
Threshold snippets
Fragmentation view
Threshold count: 10
Common snippets: BRAF V600E | EGFR Exon 19 deletion | KRAS G12C
Threshold label: Fragmented
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04746924 | https://clinicaltrials.gov/study/NCT04310007 | https://clinicaltrials.gov/study/NCT07416058 | https://clinicaltrials.gov/study/NCT04591431 | https://clinicaltrials.gov/study/NCT03049618 | https://clinicaltrials.gov/study/NCT02367781 | https://clinicaltrials.gov/study/NCT04790409 | https://clinicaltrials.gov/study/NCT07393555 | https://clinicaltrials.gov/study/NCT04841538 | https://clinicaltrials.gov/study/NCT03958097 | https://clinicaltrials.gov/study/NCT05800015 | https://clinicaltrials.gov/study/NCT04900363 | https://clinicaltrials.gov/study/NCT07082179 | https://clinicaltrials.gov/study/NCT05756972 | https://clinicaltrials.gov/study/NCT04033354 | https://clinicaltrials.gov/study/NCT04507217 | https://clinicaltrials.gov/study/NCT06868836 | https://clinicaltrials.gov/study/NCT06969027 | https://clinicaltrials.gov/study/NCT03952403 | https://clinicaltrials.gov/study/NCT03594747 | https://clinicaltrials.gov/study/NCT04440943 | https://clinicaltrials.gov/study/NCT02908906 | https://clinicaltrials.gov/study/NCT04244552 | https://clinicaltrials.gov/study/NCT03554473 | https://clinicaltrials.gov/study/NCT02927301 | https://clinicaltrials.gov/study/NCT05262985